We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Chief executive claims Republican state government ‘rushed’ process when passing sweeping restrictions
Verge says ALS therapy is one of the first to be developed by a tech-enabled platform
Pharmaceutical company says new legislation will hinder its ability to attract diverse talent
On paper the obesity drug market is huge but mass adoption of the treatments would strain health budgets
Late-stage trial of Tirzepatide could be a ‘potential breakthrough’ in treatment, says US drugmaker
Pharma executive warns policymakers may be incapable of preparing the public for next pandemic
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
US drugmaker says independent probe was sparked by claims of a personal relationship with an employee
Studies suggest antibody therapies are less effective against new variants
Failure rate has been dauntingly high but success would be hugely profitable
US FDA gives emergency approval to bamlanivimab therapy designed to boost immune system
Johnson & Johnson and Eli Lilly announce pauses in blow to hopes for pandemic remedy
Early signs are promising but there will be limits on how much the drug companies can charge
Antibody would be one of first treatment options for patients with mild or moderate illness
Setback deals another blow to most common hypothesis about causes of the disease
Pharmaceuticals company said revenue driven by selling more drugs, not raising prices
Cheaper option was unveiled shortly before company was grilled by Congress about soaring prices
Pharma group beats expectations despite competition knocking erectile dysfunction drug sales
Amgen, Merck and Eli Lilly say Trump administration’s move infringes on free speech
Pfizer, Eli Lilly and Merck raise earnings forecasts for 2019
Animal health spin off helps pharmaceutical group raise earnings forecasts
Move comes amid persistent criticism over rising US drug prices
Deal is latest by large pharma groups seeking to bolster pipelines
International Edition
